诊断生长抑素受体阳性神经内分泌肿瘤的新一代放射性试剂Copper Cu 64 dotatate  

Copper Cu 64 dotatate,a new diagnostic agent for somatostatin receptor-positive neuroendocrine tumors

作　　者：胥明珠 陈超阳[1] 魏然 张玄龄 周颖[1,2] XU Ming-zhu;CHEN Chao-yang;WEI Ran;ZHANG Xuan-ling;ZHOU Ying(a.Department of Pharmacy;b.Drug Clinical Trial Facility,Peking University First Hospital,Beijing 100034,China;School of Basic Medicine and Clinical Pharmacy,China Pharmaceutical University,Nanjing 210009,Jiangsu Province,China)

机构地区：[1]北京大学第一医院药剂科,北京100034 [2]北京大学第一医院药物临床试验机构,北京100034 [3]中国药科大学基础医学与临床药学学院,江苏南京210009

出　　处：《中国临床药理学杂志》2024年第12期1832-1834,共3页The Chinese Journal of Clinical Pharmacology

摘　　要：2020-09-03,美国食品药品监督管理局(FDA)正式批准美国RadioMedix公司研发的Copper Cu 64 dotatate(商品名:Detectnet)用于成人患者生长抑素受体阳性神经内分泌肿瘤的诊断。Copper Cu 64 dotatate是一种放射性诊断试剂,与生长抑素受体结合并发射正电子(β+)的放射性核素,其发射量允许正电子发射断层扫描(PET)成像。本文现对其作用机制、药代动力学、临床研究、安全性等方面进行介绍。On September 3, 2020, the U.S. Food and Drug Administration(FDA) granted formal approval to Copper Cu 64 dotatate(commercially known as Detectnet), for its pivotal role in diagnosing somatostatin receptor(SSTR) positive neuroendocrine tumors(NETs) in adult patients. This innovative diagnostic agent, Copper Cu 64 dotatate, is a sophisticated radionuclide that selectively targets somatostatin receptors, facilitating the emission of positron(β+) radionuclides in a quantity conducive for high-resolution positron emission tomography(PET) imaging. This review delves into the intricate mechanisms of action, the dynamic pharmacokinetics, comprehensive clinical studies, and the safety profile of Copper Cu 64 dotatate, highlighting its significance in the realm of medical diagnostics.

关 键 词：Copper Cu 64 dotatate 神经内分泌肿瘤 生长抑素受体 

分 类 号：R981[医药卫生—药品]